Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Liposarcoma


Related Diseases
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

How might liposarcoma be treated?

The treatment for liposarcoma depends on the type, size, and location of the tumor.  Surgery to remove the tumor is often the first treatment.  When the tumor is in the abdomen, it may be difficult to remove completely, especially if the tumor is growing near important organs that cannot be removed.  If the entire tumor cannot be removed during surgery, radiation therapy may be used after surgery to kill any cancer cells that remain to reduce the chance of the tumor coming back (a recurrence).   Chemotherapy is another treatment that can kill remaining cancer cells following surgery, though it is not usually used to treat low-grade sarcomas. [1] [2]

Sometimes radiation therapy or chemotherapy may be done prior to surgery to shrink the tumor; this may increase the chance of removing the whole tumor during surgery while limiting the impact to other organs. [1] [2]
Last updated: 2/18/2011

References
  1. Adult Soft Tissue Sarcoma Treatment Health Professional Version. National Cancer Institute. January 24, 2011; http://www.cancer.gov/cancertopics/pdq/treatment/adult-soft-tissue-sarcoma/HealthProfessional. Accessed 2/14/2011.
  2. Soft Tissue Sarcoma. National Comprehensive Cancer Network. February 1, 2011; http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed 2/14/2011.


Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Liposarcoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Eribulin mesylate
Trade Name
(Manufacturer Name)
Halaven
(Eisai, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Trabectedin
Trade Name
(Manufacturer Name)
Yondelis
(Janssen Research & Development, LLC)
Indication
The FDA has approved this product to be used in this manner.
For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
More Information about this product Drug Information Portal
Medline Plus Health Information

Related Diseases
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.